Ebola Vaccines
11.4.26 The World Health Organization (WHO) has recommended adding two new candidate vaccines—to clinical trials to fight the Bundibugyo strain of the Ebola virus. ChAdOx1 BDBV Oxford-developed vaccine recommended to enter pivotal trial against deadly Bundibugyo virus “Every week this outbreak continues, more families and communities in the DRC are devastated, and the need for a vaccine against Bundibugyo virus grows more urgent. Thanks to the commitment of our partners at the University of Oxford and the Serum Institute of India, this promising candidate went from concept to clinical trials in a matter of weeks. Its recommendation for inclusion in the Tumaini study is an important step towards a BDBV-specific vaccine that can protect those most at risk.” CEPI is funding the development of the ChAdOx1 BDBV vaccine candidate and is providing funding, scientific expertise and operational support to the Tumaini trial. Approximately 620,000 doses of the ChAdOx1 BDBV vaccine candidate ...